InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise
April 25, 2024
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Abstract to Be Presented Next Month at ASCO Annual Meeting
April 25, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, announced that its abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (“ASCO”) annual meeting. This year’s meeting is slated for May 31–June 4, 2024, in Chicago. According to the company, the abstract contains data and results […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update
April 1, 2024
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Present at Three Upcoming Events
February 22, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be represented at three upcoming conferences: the BIO CEO & Investor Conference, the 2024 NeauxCancer Oncology Conference and H.C. Wainwright’s first Artificial Intelligence Based Drug Discovery & Development virtual conference. According to the announcement, POAI CEO Raymond F. Vennare will […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Participation in January Conferences
January 2, 2024
Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be attending three upcoming conferences: Biotech Showcase, LifeSco Partners Corporate Access Event and BIO Partnering@JPM Week 2024. All three events are slated for Jan. 8–10, 2024, in San Francisco. According to the announcement, POAI CEO Raymond F. Vennare will be […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 2023 Financial Results, Business Update
November 14, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, is reported its financial and operating results for the three- and nine-month periods ending Sept. 30, 2023. Highlights of the […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), UPMC Magee-Womens Hospital Complete Ovarian Cancer Study
November 8, 2023
Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, has completed a multiyear study through a partnership with UPMC Magee-Womens Hospital. The study was focused on evaluating the use of AI in building multiomic machine learning (“ML”) models and then testing the models to determine if they could learn associations between […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Schedules Release of Q3 Results, Corporate Update Call
November 7, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is planning to release its financial results for Q3 2023. The company announced it […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 2023 Financial Results, Corporate Update
August 11, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is reporting on its Q2 2023 performance. The company reported financial and operating results […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Plans to Release Q2 2023 Financial Results, Host Earnings Call
August 3, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development will report its financial results next week. The company announced that it will release […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Moves Corporate HQ to Pittsburgh
July 18, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is moving to Pittsburg. The company announced that it has relocated […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Finance Veteran as Newest Business Advisory Board Member
June 27, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, has appointed a new member to its business advisory board. The […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Advisory Board Appointment of Dr. Bernard A. Harris, Jr.
June 20, 2023
Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development. The company today announced the appointment of Dr. Bernard A. Harris, Jr. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Present Groundbreaking PEDAL Approach at 2023 BIO International Convention
May 23, 2023
Predictive Oncology (NASDAQ: POAI) today announced that its Chief Business Officer Pamela Bush, Ph.D., MBA will present at the upcoming 2023 BIO International Convention, in Boston, Massachusetts, on June 5, 2023. Dr. Bush, beginning at 2:45 p.m. ET in presentation room 103, will discuss the importance of addressing patient heterogeneity in drug discovery and the […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2023 Financial Report, Business Update
May 16, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the three months ended March 31, 2023. According to the report, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Report First Quarter 2023 Results, Host Conference Call and Webcast
May 8, 2023
Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development. The company today announced that it will report its financial results for […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Seasoned Veteran as New Board Member
May 3, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, announced the appointment of a new board member. healthcare commercial and business development veteran Veena Rao, PhD., MBA, will be serving […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reverse Stock Split Approved, Effective April 24
April 21, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a reverse stock split of its common stock. According to the announcement, the stock split will be effective Monday, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Special Meeting of Stockholders Rescheduled after ‘Lack of Required Quorum’
April 18, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has adjourned its Special Meeting of stockholders. The company held the meeting on April 17, 2023, at 3 p.m., and then […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Oncology Translational Research Leader to Scientific Advisory Board
April 4, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has appointed Christoph Reinhard, PhD, MBA, to its Scientific Advisory Board. Reinhard will join other board members who are thought leaders […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Integra Therapeutics Collaborate to Advance Gene Therapy
March 30, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to the announcement, the collaboration was created to pursue a novel method to […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates to Leverage AI for New Cancer Drugs, Announces 2022 Results
March 22, 2023
Predictive Oncology’s (NASDAQ: POAI) chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, joined Proactive’s Natalie Stoberman to discuss their partnership for new cancer drug development. According to the announcement, “The collaboration will utilize Predictive Oncology’s PEDAL technology [an artificial intelligence (‘AI’) and machine learning platform] to evaluate Cancer […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Key Partnership, Declares Dividend
March 17, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is collaborating with Cancer Research Horizons in the development of oncology drugs utilizing its proprietary PEDAL(TM) platform. Cancer Research Horizons is the […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Engages with Leading IR Consultant to Implement Comprehensive IR Effort
March 14, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a new partnership. The company is working with LifeSci Advisors to implement a comprehensive IR program. The company anticipates […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Updates Shareholders, Provides Company Overview and Plans for Future
March 9, 2023
Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare has issued a letter to shareholders, providing an overview of the company and a look at the significant progress the company has made in respect to validating its commercial platform and publishing its proof of concept. In the letter, Vennare noted that Predictive Oncology is now in a […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Talks New Cvergenx Partnership During Proactive Interview
March 1, 2023
Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare was a featured guest during the latest interview released by Proactive US. Vennare joined Cvergenx CEO Javier Torres-Roca to talk about the recent announcement that the two companies have joined forces to create a new genomic-based artificial intelligence (“AI”) radiation therapy. Host Natalie Stoberman facilitated the discussion, in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Cvergenx Inc. to Collaborate in Novel Approach to Personalized Radiotherapy and Drug Discovery
February 23, 2023
Predictive Oncology (NASDAQ: POAI) and Cvergenx today announced an agreement to form a strategic partnership that will potentially revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery. According to the announcement, the collaboration’s objective is to leverage and maximize the combined power of proprietary technologies […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Chief Business Officer
February 22, 2023
Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery, has announced the appointment of a new chief business officer. The company has named veteran Pamela Bush to the role. Bush was featured during a recent Proactive video release, during which she and host Natalie Stoberman discussed her new assignment. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Program to Partner Academic, Research Institutions to Assist with Drug-Discovery Initiatives
February 21, 2023
Predictive Oncology (NASDAQ: POAI) launched a program designed to advance the oncology drug-development initiatives with academic and research institutions. The program, called ACE, partners with early-stage academic and research institutions to assist in advancing their efforts and focus on drug discovery. The program provides access to POAI’s PEDAL platform, which brings together active machine learning with […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer
February 3, 2023
Predictive Oncology (NASDAQ: POAI) has announced a new chief business officer. Effective immediately, Pamela Bush, PhD, MBA, will take on the role as chief business officer and will oversee all business development including the partnering and growth strategies for the company. Specifically, the company observed that she will manage the company’s strategic, operational and financial […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Computational Biology Pioneer as New Scientific Advisory Board Member
January 12, 2023
Predictive Oncology (NASDAQ: POAI) has announced a new member of its Scientific Advisory Board: Robert F. Murphy, PhD, a pioneer in the field of machine learning and analytics for biological data, will be joining the board and working with other experts in a variety of fields to guide the POAI’s scientific initiatives and growth strategy. […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Expands Scientific Advisory Board to Appoint Genomics Expert
December 13, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of Marc Malandro, Ph.D., to the company’s scientific advisory board. Dr. Malandro, a highly regarded scientific leader and expert in genomics, molecular biology, biochemistry and bioengineering, will serve alongside other key thought […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Member
December 5, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initiatives and commercialization efforts.” A well-known business executive in the pharma and biotech industries, Hawryluk currently serves as executive vice […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 Financial Report, Corporate Update
November 11, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting corporate updates and financial results for its Q3 quarter, ended Sept. 30, 2022. According to the announcement, the report reflects revenue growth and increased gross profit margin as compared to prior year periods. Highlights […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Key Life Sciences Thought Leader to Its Board
October 25, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its appointment of David S. Smith, JD, to the company’s board of directors. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Seasoned Senior Exec, Biotech Entrepreneur as New CEO
October 20, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Raymond F. Vennare as its new chief executive officer, effective Nov. 1, 2022; Vennare will also assume the role of board chair. Vennare has more than 30 years’ experience building and leading biotechnology and […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report
August 12, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ended June 30, 2022. In addition, the company also released a corporate update for the company, […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report
August 12, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its numbers for second quarter 2022, or the period ended June 30, 2022. According to the announcement, the report indicates a strong balance sheet with a solid cash balance, commensurate equity and no debt. […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Chief Scientific Officer, Shares R&D Update
July 26, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Julia Kirshner, PhD, as its new chief scientific officer. Kirshner has been serving as POAI’s senior vice president as well as president of the company’s zPREDICTA division, a company that she originally founded in […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.2M in Registered Direct Offerings
May 19, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on two direct offerings. The offerings, which were available concurrently, were with different institutional investors and results in approximately $7.2 million in gross proceeds for the company, before the deduction of […]